Following Alvotech and Advanz Pharma?
Get the free weekly contract digest
The latest new contracts, like Alvotech and Advanz Pharma’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Alvotech and Advanz Pharma Announce EMA Acceptance of Marketing Authorization Application for AVT06, a Proposed Biosimilar to Eylea®
Aug 15, 2024•almost 2 years ago
Contract Type
partnership
ManufacturingBiotechnologyPharmaceutical
Description
Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), marking a step closer to making AVT06 available in Europe to provide patients with more treatment options.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months